No Data
Xiamen Amoytop Biotech's (SHSE:688278) 44% CAGR Outpaced the Company's Earnings Growth Over the Same Three-year Period
Xiamen Amoytop Biotech's Electronic Pen Injector Gets Registration Certificate From China's Fujian Province
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Tebao Biotech: Tepo Biotech: 2024 Annual Results Forecast
Tebao Biotech: 2024 Annual Results Forecast
The sales growth of the Paigebin product drives performance increase, with Xiamen Amoytop Biotech achieving a new high in net profit in Q4.
① With the continuous upgrade of hepatitis B chronic prevention and treatment guidelines and the ongoing accumulation of clinical cure scientific evidence, cognitive awareness will be promoted, and the number of patients accepting treatment will show an upward trend; ② Interferon has common side effects such as flu-like symptoms, and relatively, patients have a greater workload in treatment and management, which may affect the treatment choices between doctors and patients.
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today